A connected testing guide to glucose diagnosis, kidney protection, cardiovascular risk, and meaningful follow-up.
Prediabetes and type 2 diabetes cannot be understood from one number alone. An A1C test estimates average glucose exposure over about two to three months, a fasting plasma glucose test measures one carefully timed point, and a two-hour 75-gram oral glucose tolerance test (OGTT) shows how the body handles a standardized glucose challenge. The results may agree, but they do not always do so.
Glucose results also do not show the full cardiometabolic picture. urine albumin-to-creatinine ratio (UACR), creatinine-based estimated glomerular filtration rate (eGFR), and a lipid panel help reveal kidney and cardiovascular risk that may be present even when a person feels well.
Medical note: Laboratory testing provides information; it does not replace professional evaluation. Do not diagnose yourself or start, stop, or change medication based on a direct-access result. Diagnostic-range or unexpected results should be reviewed promptly with a qualified healthcare professional.
Direct answer: Prediabetes means blood glucose is above the usual range but below the diagnostic threshold for diabetes. Type 2 diabetes develops when insulin resistance and progressive loss of pancreatic beta-cell function allow glucose to remain elevated.
The process often begins years before classic symptoms appear. Early in insulin resistance, the pancreas may produce more insulin to keep fasting glucose near the reference range. Post-meal glucose may rise first. Later, fasting glucose and A1C may also increase as beta-cell compensation becomes less effective.
That progression explains why symptoms alone are unreliable. Some people have increased thirst, frequent urination, fatigue, blurred vision, recurrent infections, or slow wound healing. Others have no noticeable symptoms. Objective laboratory testing can identify the glucose pattern and establish a baseline for follow-up.
Risk is higher with age, family history, overweight or central adiposity, physical inactivity, previous gestational diabetes, polycystic ovary syndrome, hypertension, high triglycerides, low HDL cholesterol, cardiovascular disease, metabolic dysfunction-associated steatotic liver disease, and certain medications. Current American Diabetes Association (ADA) guidance recommends routine adult screening beginning at age 35, with earlier testing when risk factors or symptoms are present.[1]
Hemoglobin A1C reflects the percentage of hemoglobin with glucose attached and estimates average glucose exposure over approximately two to three months. It does not require fasting and is useful for both screening and monitoring. However, it is an average: it may not reveal post-meal spikes, overnight lows, or large day-to-day swings.
Fasting glucose is measured after at least eight hours without caloric intake. It is a direct glucose measurement, but it can vary with acute illness, sleep disruption, stress, corticosteroids, recent dietary changes, and collection conditions. A normal fasting result does not exclude abnormal post-meal glucose handling.
The 75-gram OGTT with fasting and two-hour specimens can identify impaired glucose tolerance when A1C or fasting glucose is less remarkable. It is less convenient and requires careful preparation, but it directly evaluates the response to a standardized glucose load.
A random plasma glucose result of 200 mg/dL or higher can establish diabetes when accompanied by classic symptoms or a hyperglycemic crisis. An isolated random elevation without classic symptoms generally requires confirmation.[2]
| Test | Usual range | Prediabetes range | Diabetes range |
|---|---|---|---|
| A1C | Below 5.7% | 5.7% to 6.4% | 6.5% or higher |
| Fasting plasma glucose | 99 mg/dL or below | 100 to 125 mg/dL | 126 mg/dL or higher |
| Two-hour 75-g OGTT glucose | 139 mg/dL or below | 140 to 199 mg/dL | 200 mg/dL or higher |
| Random plasma glucose | No screening cutoff | No prediabetes cutoff | 200 mg/dL or higher with classic symptoms or crisis |
These thresholds apply to laboratory testing in nonpregnant people. Pregnancy uses different protocols and cutoffs. In the absence of unequivocal hyperglycemia, two abnormal results are generally required to confirm diabetes.
Discordance is not a reason to average the numbers. If A1C is in the diabetes range but fasting glucose is not, or if fasting glucose is normal but the two-hour OGTT is high, the result above the threshold should be repeated promptly or confirmed with another validated diagnostic test. Two abnormal results can come from the same test on different days or from two different tests, including tests collected on the same day.[1]
When A1C differs substantially from direct glucose measurements, consider factors that alter red blood cells or the assay. A complete blood count (CBC), ferritin, iron, and TIBC panel, and vitamin B12 and folate panel may help evaluate selected causes such as anemia or nutrient deficiency. Recent bleeding, transfusion, hemolysis, pregnancy, kidney failure, and hemoglobin variants can also distort A1C.[3]
| Symptom or risk factor | What it may suggest | Tests that may add information |
|---|---|---|
| Thirst, frequent urination, blurred vision | Possible symptomatic hyperglycemia | Plasma glucose and A1C |
| Central weight gain, high triglycerides, low HDL, hypertension | Insulin resistance and cardiometabolic risk pattern | A1C and glucose panel, lipid panel, and optional ApoB |
| Previous gestational diabetes or polycystic ovary syndrome | Higher future risk of dysglycemia | A1C, fasting glucose, or OGTT as clinically appropriate |
| Foamy urine, edema, long-standing diabetes | Possible kidney involvement, although early disease is often silent | UACR plus creatinine/eGFR |
| Numbness, tingling, anemia, long-term metformin use | Diabetic neuropathy is possible, but B12 deficiency or another cause may coexist | Vitamin B12, methylmalonic acid when appropriate, and CBC |
| Unexpected weight loss, ketosis, rapid progression, early insulin requirement | Diabetes classification may need review | Clinician-directed GAD-65 antibody, IA-2 antibody, ZnT8 antibody, and selected C-peptide testing |
Serum creatinine is used to calculate eGFR, an estimate of kidney filtration. UACR measures albumin leakage into urine. A person can have increased UACR while eGFR remains preserved, or a reduced eGFR with little albuminuria. That is why ADA guidance recommends at least annual assessment of both markers in all people with type 2 diabetes; testing may be more frequent when chronic kidney disease is present or the clinical situation changes.[4]
A normal creatinine value alone does not exclude early kidney damage. A practical pair is random urine albumin with creatinine plus blood creatinine/eGFR from a comprehensive metabolic panel (CMP). A Kidney Profile can group these complementary markers.
UACR can rise temporarily after strenuous exercise or during fever, urinary infection, menstruation, marked hyperglycemia, uncontrolled blood pressure, or acute illness. An unexpected elevation usually needs confirmation under more stable conditions rather than an immediate conclusion from one sample.[5]
Type 2 diabetes commonly clusters with high triglycerides, low HDL cholesterol, increased atherogenic lipoprotein particles, hypertension, and vascular disease. A lipid panel with ratios measures total cholesterol, LDL cholesterol, HDL cholesterol, and triglycerides. It helps a healthcare professional assess cardiovascular risk and monitor the response to an individualized plan.
ApoB testing estimates the number of atherogenic lipoprotein particles and may add context when triglycerides are elevated, LDL cholesterol and the broader risk pattern appear discordant, or a clinician wants additional risk refinement. It is not necessary for every person. Cardiovascular risk interpretation also depends on age, blood pressure, smoking, kidney disease, family history, and known cardiovascular disease.[6]
The most useful test depends on the question being asked. The table below separates essential diagnostic tests from kidney and cardiovascular assessment, A1C-discordance evaluation, and selected classification testing.
| Test | What it measures and why it matters | Important limitations |
|---|---|---|
| A1C | Average glucose exposure over about two to three months; used for screening, diagnosis, and monitoring. | May be inaccurate when red cell turnover, hemoglobin variants, pregnancy, kidney failure, or recent blood loss alters the result. |
| Fasting or random plasma glucose | Direct glucose concentration at collection; fasting values support screening and diagnosis, while random values are interpreted with symptoms. | One point in time; affected by fasting status, illness, stress, sleep, and medications. |
| Two-hour 75-g OGTT | Fasting and two-hour glucose response to a standardized load; can detect impaired glucose tolerance missed by fasting glucose. | Requires fasting, correct preparation, and a longer collection visit; pregnancy protocols differ. |
| UACR | Albumin leakage relative to urine creatinine; can identify kidney damage before eGFR falls. | Temporary elevations occur; persistence generally requires repeat confirmation. |
| CMP with creatinine/eGFR | Glucose, creatinine, electrolytes, and liver-related biomarkers; supports kidney function and medication-safety context. | eGFR is an estimate; creatinine is influenced by muscle mass and other factors. A normal CMP does not replace UACR. |
| Lipid panel | Total cholesterol, LDL-C, HDL-C, and triglycerides; informs cardiovascular risk assessment. | Targets are individualized; very high triglycerides or treatment changes may require fasting follow-up. |
| ApoB | Atherogenic particle number; can refine risk when standard lipid measures are discordant. | Not routinely needed for everyone and does not replace a full risk assessment. |
| CBC and iron studies | Evaluates anemia, red-cell indices, and iron status when A1C appears discordant or fatigue is present. | Abnormal findings have many possible causes and need clinical interpretation. |
| Vitamin B12 with optional methylmalonic acid | Evaluates B12 status, especially with neuropathy, anemia, malabsorption risk, or long-term metformin exposure. | Serum B12 can be borderline; methylmalonic acid also rises with reduced kidney function. |
| TSH with reflex to free T4 | Evaluates thyroid function when symptoms, history, or lipid patterns suggest a thyroid contribution. | Not a diabetes diagnostic test and should be symptom- or history-directed. |
| GAD-65, IA-2, and ZnT8 antibodies | Autoimmune markers used when type 1 diabetes or adult autoimmune diabetes is a concern. | Selected, clinician-directed testing; antibody results do not replace the full clinical picture. |
| C-peptide | Reflects endogenous insulin production and can assist classification in selected insulin-treated patients. | Interpretation depends on concurrent glucose, kidney function, timing, and treatment; not a routine screening test. |
A staged approach helps answer the most important question without implying that everyone needs every test.
Reference ranges are not the same as individualized goals. Diagnostic cutoffs identify categories, while treatment goals depend on age, duration of diabetes, pregnancy, cardiovascular and kidney disease, hypoglycemia risk, medications, and personal circumstances. The range printed by the laboratory should be interpreted alongside the collection method and clinical question.
Results can vary with fasting status, hydration, recent meals, exercise, acute illness, sleep, stress, supplements, medications, pregnancy, and laboratory methodology. A mildly abnormal result does not always mean disease, and a result inside the reference range does not always rule out an important health concern.
Trends are often more informative than isolated values, but only when the same test, units, and collection conditions are reasonably comparable. Keep the full report, note whether you fasted, and review unexpected shifts with a healthcare professional.
Always review the preparation instructions for the specific test or panel before ordering because requirements can differ.
Ulta Lab Tests allows patients to order many diabetes and prediabetes blood tests directly online where available. Testing is performed through established laboratory networks such as Quest Diagnostics, where applicable. Pricing is displayed before ordering, no insurance is required, HSA/FSA payment may be available where accepted, and results are delivered through a secure online portal.
Direct access is most useful when it supports an informed conversation. Choose tests that answer a defined question, follow preparation instructions, and share diagnostic-range or unexpected results with a qualified healthcare professional.
Seek urgent medical care for marked thirst and urination with unexplained weight loss, persistent vomiting or abdominal pain, deep or rapid breathing, fruity-smelling breath, confusion, severe weakness, unusual sleepiness, very high glucose with dehydration, moderate or high ketones, fainting, seizure, chest pain, stroke symptoms, or severe shortness of breath. These findings can signal diabetic ketoacidosis, hyperosmolar hyperglycemic state, severe hypoglycemia, or another emergency and should not wait for routine outpatient retesting.[9]
The validated laboratory options are A1C, fasting plasma glucose, and the two-hour glucose value from a 75-gram OGTT. Each identifies a different aspect of dysglycemia. A1C reflects a longer-term average, fasting glucose measures a standardized moment, and OGTT evaluates glucose handling after a challenge. A diagnostic-range result may require confirmation.
Yes. A1C is an average and may remain below a diagnostic threshold even when two-hour glucose is elevated. This may occur when fasting glucose is relatively preserved but post-challenge glucose handling is impaired. A clinician may consider an OGTT when risk is high, symptoms or home patterns raise concern, or A1C and fasting glucose do not answer the question.
Neither is universally more accurate; they measure different things and have different limitations. Fasting glucose varies day to day and depends on preparation. A1C is less affected by short-term changes but can be distorted by altered red-cell survival, anemia, hemoglobin variants, pregnancy, or kidney failure. Agreement between methods increases confidence; discordance deserves investigation.
Not always. In an asymptomatic person without unequivocal hyperglycemia, diabetes generally requires two abnormal results. That may be a repeat A1C of 6.5% or higher, or another diagnostic test above its diabetes threshold. A healthcare professional should confirm the result, review possible A1C interference, and determine the diabetes type before treatment decisions are made.
eGFR estimates how well the kidneys filter blood, while UACR measures albumin leakage into urine. Kidney damage can first appear as albuminuria while filtration remains preserved, and filtration can decline with little albuminuria. Reading both markers together provides a more complete view of kidney status and cardiovascular-kidney risk than either result alone.
A1C measures glucose exposure, not atherosclerotic risk. Type 2 diabetes often occurs with elevated triglycerides, low HDL cholesterol, increased atherogenic particles, and hypertension. A lipid panel helps assess that separate but connected cardiovascular pattern. ApoB may add particle-number information for selected people, but it is not required for everyone.
No. A fasting insulin test can provide context in selected clinical or research settings, but validated diagnosis relies on A1C or plasma glucose criteria. Insulin assays are not standardized enough to replace those tests, and an elevated insulin value does not independently establish diabetes. Interpret insulin only with glucose, clinical context, and professional guidance.
No. Home meters and continuous glucose monitors can identify patterns and support diabetes management, but laboratory testing is the standard diagnostic pathway. Consumer readings can be affected by device performance, technique, timing, and interstitial-versus-plasma differences. Concerning readings should prompt timely laboratory confirmation and professional evaluation.
For established diabetes, glycemic status is commonly assessed about every three months when treatment changes or goals are not being met, and about twice yearly when glucose is stable and within the individualized goal range. Prediabetes is generally reassessed at least annually. The interval should be individualized by a healthcare professional.
Ulta Lab Tests offers direct online access to many A1C, glucose, OGTT, kidney, and lipid tests where available. Direct access does not replace medical care. Diagnostic-range results, symptoms, pregnancy-related testing, possible type 1 diabetes, or medication decisions require timely review with a qualified healthcare professional.
Prediabetes blood tests are most informative when A1C, fasting glucose, and OGTT are matched to the question and interpreted with kidney and lipid testing. A1C shows longer-term exposure, fasting glucose shows a standardized point, and OGTT can uncover post-challenge dysglycemia. UACR and eGFR reveal complementary kidney risks, while a lipid panel - with ApoB when appropriate - adds the cardiovascular dimension.
Explore diabetes testing options from Ulta Lab Tests, choose only the tests that fit your purpose, and review diagnostic-range, discordant, or changing results with a qualified healthcare professional.
Prediabetes is a glucose level above the usual range but below the diagnostic threshold for diabetes; type 2 diabetes develops through insulin resistance and progressive beta-cell dysfunction. A1C, fasting glucose, and OGTT measure different aspects of glycemia, while UACR/eGFR and lipid testing show connected kidney and cardiovascular risk.
Related tests: A1C, fasting plasma glucose, two-hour 75-g OGTT, UACR, creatinine/eGFR, lipid panel, ApoB, CMP, CBC, iron studies, vitamin B12, methylmalonic acid, selected diabetes autoantibodies, and C-peptide.
How Ulta Lab Tests helps: Ulta Lab Tests provides direct online access to many relevant laboratory tests where available, with transparent pricing and secure online results.
These are generally appropriate when a healthcare professional is investigating uncertain diabetes type—not as routine prediabetes screening.
Ulta Lab Tests, LLC.
9237 E Via de Ventura, Suite 220
Scottsdale, AZ 85258
480-681-4081
(Toll Free: 800-714-0424)
